{"id":"control-vaccine-typbar-tcv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains the Vi polysaccharide capsular antigen of Salmonella typhi conjugated to tetanus toxoid, which enhances immunogenicity and promotes both T-cell and B-cell responses. This conjugate design improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against typhoid fever infection.","oneSentence":"Typbar TCV is a conjugate vaccine that stimulates immune response against Salmonella typhi by presenting purified polysaccharide antigens conjugated to a carrier protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:33.442Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever caused by Salmonella typhi"}]},"trialDetails":[{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT05475379","phase":"PHASE1, PHASE2","title":"Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-07-01","conditions":"Typhoid","enrollment":630},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Typbar TCV®"],"phase":"phase_3","status":"active","brandName":"Control Vaccine Typbar TCV®","genericName":"Control Vaccine Typbar TCV®","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Typbar TCV is a conjugate vaccine that stimulates immune response against Salmonella typhi by presenting purified polysaccharide antigens conjugated to a carrier protein. Used for Prevention of typhoid fever caused by Salmonella typhi.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}